大华继显控股有限公司将药明康德A股评级上调至买进。 ...

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec [1][6] Core Views - WuXi AppTec's 2Q25 performance significantly exceeded market expectations, leading to an upward revision of the full-year revenue guidance to a growth rate of 13%-17% YoY [1][5] - The target prices have been raised to HKD 128.5 for H shares and RMB 113.5 for A shares, reflecting a potential upside of 15% from current prices [2][6] Financial Performance Summary - In 2Q25, the company reported a revenue of RMB 11,144.7 million, representing a 20.4% increase YoY and a 15.4% increase QoQ [5][7] - The adjusted Non-IFRS net profit for 2Q25 was RMB 3,637.1 million, up 47.9% YoY and 35.8% QoQ [5][7] - The gross margin improved to 45.8%, an increase of 5.8 percentage points YoY [5][7] - The number of orders on hand reached a record high of RMB 566.9 billion, up 37.2% YoY [5][6] Revenue and Profitability Forecast - The revenue forecast for 2025 is set at RMB 45,223 million, with a projected growth rate of 15% [8][9] - The adjusted Non-IFRS net profit for 2025 is estimated at RMB 18,532 million, indicating a substantial growth of 98% compared to 2024 [8][9] - The report anticipates a continued increase in profitability driven by late-stage projects and production efficiency improvements [5][6] Market Position and Growth Drivers - The strong growth in small molecule D&M and TIDES revenues is a key driver for the company's performance [5][6] - The TIDES business saw a remarkable growth of 80.2% YoY, with a backlog of orders increasing by 48.8% YoY [5][6] - Management expects double-digit growth in continuous operating revenue in the second half of 2025 [5][6]

Core Viewpoint - Citigroup has raised its earnings per share forecasts for WuXi AppTec (02359) for 2025 to 2027 by 3%, 6%, and 7% respectively, driven by margin expansion in the chemical business, a decrease in administrative expenses, and higher investment income [1] Group 1: Earnings Forecasts - WuXi AppTec's H-share target price has been increased from HKD 95 to HKD 130, while the A-share target price has been raised from CNY 88 to CNY 119 [1] - The management has revised its 2025 guidance, expecting revenue from continuing operations to reach CNY 42.5 billion to CNY 43.5 billion, representing a year-on-year growth of 13% to 17% [1] - The previous guidance was CNY 41.5 billion to CNY 43 billion, with a year-on-year growth of 10% to 15% [1] Group 2: Management Confidence - Management anticipates double-digit growth in revenue from continuing operations in the second half of 2025 compared to both year-on-year and the first half of the year [1] - The new guidance implies a year-on-year growth of 5% to 10% and a growth of 6% to 11% compared to the first half of the year [1] - Management has expressed confidence in further improving the adjusted net profit margin for 2025 [1]

Group 1 - The core viewpoint of the article is that Citigroup has raised its earnings per share forecasts for WuXi AppTec (603259) for 2025 to 2027 by 3%, 6%, and 7% respectively, due to margin expansion driven by the chemical business, a decrease in administrative expense ratios, and higher investment income [1] - Citigroup has increased the target price for WuXi AppTec's H-shares from HKD 95 to HKD 130 and for its A-shares from CNY 88 to CNY 119, reflecting a more optimistic earnings outlook [1] - WuXi AppTec's management has raised its 2025 guidance primarily due to rapid capacity expansion rather than a surge in orders prior to the tariff war, with expected revenue from continuing operations projected to reach CNY 42.5 to 43.5 billion, representing a year-on-year growth of 13% to 17% [1] Group 2 - The management's new guidance indicates a year-on-year growth of 5% to 10% and a growth of 6% to 11% compared to the first half of the year, with confidence in further improving the adjusted net profit margin for 2025 [1] - The management anticipates double-digit growth in revenue from continuing operations in the second half of 2025 compared to both year-on-year and the first half of the year [1]

Investment Rating - The investment rating for the company is "Accumulate" [5][19]. Core Insights - The company, WuXi AppTec, has shown strong performance in the first half of 2025, with a significant increase in orders on hand by 37%, leading to an upward revision of its full-year performance guidance [2][11]. - The revenue for the first half of 2025 reached RMB 20.8 billion, representing a year-on-year growth of 20.6%, with the revenue from continuing operations growing by 24.2% [11]. - The adjusted net profit margin improved to 30.4%, an increase of 5 percentage points year-on-year [11]. - The TIDES business segment has experienced rapid growth, with revenue in the first half of 2025 increasing by 141.6% year-on-year [11]. - The company has raised its full-year revenue guidance from RMB 415-430 billion to RMB 425-435 billion, expecting a return to double-digit growth in continuing operations [11]. Financial Summary - The projected total revenue for 2025 is RMB 43.547 billion, with a growth rate of 11.0% [3][12]. - The net profit attributable to the parent company is expected to be RMB 14.684 billion in 2025, reflecting a substantial growth of 55.4% [3][12]. - Earnings per share (EPS) for 2025 is projected at RMB 5.11 [3][12]. - The company maintains a net asset return rate of 21.3% for 2025 [3][12]. - The price-to-earnings (P/E) ratio is estimated to be 19.30 for 2025 [3][12]. Market Data - The company's market capitalization is approximately RMB 283.459 billion [6]. - The stock price has ranged between RMB 37.29 and RMB 98.69 over the past 52 weeks [6]. - The company has a net asset value per share of RMB 20.86, with a price-to-book (P/B) ratio of 4.7 [7].

Core Viewpoint - Citigroup reports that WuXi AppTec's management has raised its 2025 guidance primarily due to rapid capacity expansion rather than a surge in orders prior to the tariff war [1] Group 1: Revenue Guidance - Management expects that the revenue from continuing operations in the second half of 2025 will achieve double-digit growth both year-on-year and compared to the first half [1] - The new guidance indicates a year-on-year growth of 5% to 10% and a growth of 6% to 11% compared to the first half of 2025 [1] Group 2: Earnings Forecast - Citigroup did not significantly raise its revenue forecast for WuXi AppTec, as expectations were already adjusted following the first-quarter earnings announcement [1] - The bank has increased its earnings per share forecasts for WuXi AppTec for 2025 to 2027 by 3%, 6%, and 7% respectively, driven by margin expansion in the chemical business, a decrease in administrative expense ratios, and higher investment income [1] Group 3: Target Price Adjustment - Due to a more optimistic earnings outlook, Citigroup has raised the target price for WuXi AppTec's H-shares from HKD 95 to HKD 130 and for A-shares from CNY 88 to CNY 119 [1] - WuXi AppTec is now listed as a preferred stock in the Contract Development and Manufacturing Organization (CDMO) sector with a "Buy" rating [1]

药明康德公布第二季业绩，收入同比增长20.4%至111.4亿人民币;经调整净利润同比增长47.9%至36.4亿 人民币;经调整净利润率同比增长6.1个百分点，按季增长4.9个百分点至32.6%，药明康德业绩超出该行 预期。 智通财经APP获悉，中金发布研报称，由于近期医药行业平均估值上升，维持药明康德(02359)跑赢行业 评级，并将H股目标价上调59.9%至126港元。考虑到核心业务需求强劲及营运效率改善，上调2025及 2026年纯利预测8.9%及9.2%，至各125亿及144亿人民币。 ...

Investment Rating - The report maintains a "Buy" rating for both A-shares and H-shares of the company [5][7]. Core Insights - The company reported significant revenue growth of 20.64% year-over-year, reaching 20.799 billion yuan, and a net profit increase of 101.92%, amounting to 8.561 billion yuan in the first half of 2025 [2][3]. - The strong performance is attributed to the focus on the CRDMO business model, improved production efficiency, and a substantial increase in orders, which reached 56.69 billion yuan, up 37.2% year-over-year [3][4]. Summary by Sections Financial Performance - In Q2 2025, the company achieved revenue of 11.14 billion yuan, a year-over-year increase of 20.37%, and a net profit of 4.89 billion yuan, reflecting a 112.78% increase [2]. - The non-IFRS gross margin improved to 44.5%, an increase of 4.7 percentage points year-over-year [3]. Business Segments - The chemical business generated revenue of 16.3 billion yuan in the first half of 2025, a significant growth of 33.5% [4]. - The TIDES business showed exceptional performance, with revenue reaching 5.03 billion yuan, a year-over-year increase of 141.6% [4]. Profit Forecast and Valuation - The profit forecasts for 2025-2027 have been revised upwards to 15.14 billion yuan, 15.54 billion yuan, and 18.02 billion yuan, representing increases of 37.9%, 24.1%, and 27.3% respectively [5]. - The corresponding P/E ratios for A-shares are projected to be 19, 18, and 16 for the years 2025, 2026, and 2027 [5].

Summary of WuXi AppTec's Conference Call Company Overview - **Company**: WuXi AppTec - **Date**: July 29, 2025 Key Financial Performance - **Net Profit**: Reached 6.31 billion RMB in H1 2025, a year-on-year increase of 44.4% [2][3] - **Total Revenue**: Achieved 20.6% growth, totaling 20.8 billion RMB [3] - **Backlog Orders**: Increased to 56.69 billion RMB, up 30% year-on-year [4] - **Revenue Guidance**: Full-year revenue guidance raised to 13%-17%, expecting total revenue of 42.5-43.5 billion RMB [5][16] Regional Performance - **Global Market**: Strong performance with U.S. revenue up 38.4%, Europe up 9.2%, while China saw a decline [2][6] - **Diverse Revenue Sources**: Enhanced stability and resilience in performance due to diversified income streams [6] Business Segment Highlights - **Chemistry and DRDMO**: Revenue grew 33.5% to 16.3 billion RMB, with a gross margin increase to 49% [2][8] - **TIDES Business**: Revenue surged 141.6% to 5.03 billion RMB, with backlog orders up 48.8% [2][10] - **Small Molecule CDMO**: Revenue increased 17.5% to 8.68 billion RMB, with capacity expected to exceed 4 million liters by year-end [2][9] - **Laboratory Analysis and Testing**: Slight revenue decline to 2.69 billion RMB, but drug safety evaluation business grew [12] - **Clinical CRO and SMO**: Revenue decreased 4.7% to 800 million RMB, with SMO maintaining industry leadership [13] Sustainability Achievements - **MSCI Rating**: Achieved highest Triple A rating, first in A-share life sciences sector [7] Shareholder Returns - **Dividends**: Completed cash dividends of 3.84 billion RMB and initiated a new round of A-share buybacks [5][17] - **Stock Buybacks**: 1 billion RMB buyback plan approved [17][29] Future Outlook - **Growth Strategy**: Focus on CRDMO business model and global DNM capacity expansion [16] - **Market Trends**: Anticipated strong demand for GLP-1 drugs, with significant growth potential in peptide and small molecule drugs [21][22] Operational Insights - **Production Efficiency**: Improved production processes leading to higher gross margins, particularly in Chemistry [22] - **Inventory Growth**: Increased inventory by over 30% to support rising order demands [30] Industry Context - **BD Transactions**: Active domestic innovation drug BD transactions enhancing industry sentiment [27] - **Market Dynamics**: Stable pricing trends observed in the market, with a focus on high-quality clients [27] This summary encapsulates the key points from WuXi AppTec's conference call, highlighting financial performance, business segment growth, sustainability efforts, shareholder returns, and future outlook.

Core Viewpoint - WuXi AppTec reported a 20.4% year-on-year revenue growth to 11.14 billion yuan for Q2, with adjusted net profit increasing by 47.9% to 3.64 billion yuan, and an adjusted net profit margin rising by 6.1 percentage points year-on-year and 4.9 percentage points quarter-on-quarter to 32.6% [1] Financial Performance - Revenue for Q2 reached 11.14 billion yuan, marking a 20.4% increase compared to the previous year [1] - Adjusted net profit for the same period was 3.64 billion yuan, reflecting a 47.9% year-on-year growth [1] - Adjusted net profit margin improved to 32.6%, up 6.1 percentage points year-on-year and 4.9 percentage points quarter-on-quarter [1] Future Outlook - The company’s performance exceeded expectations, prompting an upward revision of net profit forecasts for 2025 and 2026 by 8.9% and 9.2%, respectively, to 12.5 billion yuan and 14.4 billion yuan [1] - Due to the recent increase in average valuations in the pharmaceutical industry, the target price for WuXi AppTec's A-shares has been raised by 45.9% to 115 yuan, and the target price for H-shares has been increased by 59.9% to 126 Hong Kong dollars [1]